Published in Am J Respir Crit Care Med on December 10, 2009
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study | NCT00131274
Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med (2012) 6.15
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Pulmonary fibrosis: patterns and perpetrators. J Clin Invest (2012) 2.05
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol (2011) 1.82
Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair (2012) 1.37
Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med (2015) 1.28
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov (2010) 1.24
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis (2011) 1.20
A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis (2013) 1.18
Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair (2010) 1.17
Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis. Biochim Biophys Acta (2013) 1.11
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs (2011) 1.03
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J (2015) 1.03
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med (2014) 1.02
Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther (2010) 1.02
Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung (2012) 0.98
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death Dis (2013) 0.98
Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol (2013) 0.94
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
Novel Mechanisms for the Antifibrotic Action of Nintedanib. Am J Respir Cell Mol Biol (2016) 0.93
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov (2015) 0.93
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 0.91
Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling. Thorax (2011) 0.90
Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair (2014) 0.89
Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. Fibrogenesis Tissue Repair (2012) 0.89
Interstitial lung disease in scleroderma. Rheum Dis Clin North Am (2015) 0.88
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. FASEB J (2013) 0.88
Idiopathic pulmonary fibrosis and cancer: do they really look similar? BMC Med (2015) 0.88
Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest (2016) 0.86
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? Drugs (2016) 0.85
The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir Res (2013) 0.85
Mechanisms, Management, and Treatment of Fibrosis in Patients with Inflammatory Bowel Diseases. Gastroenterology (2016) 0.83
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther (2013) 0.83
Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res (2013) 0.83
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases. PPAR Res (2012) 0.81
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis (2015) 0.80
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy? Multidiscip Respir Med (2012) 0.80
Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4. J Exp Med (2016) 0.80
Overexpression of inhibitor of DNA-binding 2 attenuates pulmonary fibrosis through regulation of c-Abl and Twist. Am J Pathol (2015) 0.80
Idiopathic Pulmonary Fibrosis: Adaptive Multiple Features Method Fibrosis Association with Outcomes. Am J Respir Crit Care Med (2016) 0.79
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med (2016) 0.79
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies. Int J Rheumatol (2011) 0.79
New approaches to modulating idiopathic pulmonary fibrosis. Curr Allergy Asthma Rep (2013) 0.79
New perspectives on management of idiopathic pulmonary fibrosis. Ther Adv Chronic Dis (2016) 0.79
Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis. Sci Rep (2014) 0.79
Investigational approaches to therapies for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs (2010) 0.79
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway. Eur J Pharmacol (2015) 0.78
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal (2011) 0.78
Clinical trials and tribulations--lessons from pulmonary fibrosis. QJM (2012) 0.78
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis. Can Respir J (2014) 0.78
A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology. Physiol Rep (2014) 0.77
Advances in the management of idiopathic pulmonary fibrosis. F1000 Med Rep (2010) 0.77
Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol (2012) 0.77
Fibrogenesis, novel lessons from animal models. Semin Immunopathol (2015) 0.77
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2016) 0.77
Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy. Semin Immunopathol (2015) 0.77
A Mathematical Model of Idiopathic Pulmonary Fibrosis. PLoS One (2015) 0.77
Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 0.75
Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis. Drug Des Devel Ther (2015) 0.75
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review. Clin Case Rep (2016) 0.75
The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med (2015) 0.75
Promising new treatment targets in patients with fibrosing lung disorders. World J Clin Cases (2014) 0.75
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer (2016) 0.75
Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis. Am J Respir Cell Mol Biol (2017) 0.75
Lymphatic Changes in Respiratory Diseases: More Than Just Remodeling of the Lung? Am J Respir Cell Mol Biol (2017) 0.75
Lung epithelial cell focal adhesion kinase signaling inhibits lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology (2009) 9.51
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
Pneumocystis pneumonia. N Engl J Med (2004) 5.86
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Myocardial infarction and sudden cardiac death in Olmsted County, Minnesota, before and after smoke-free workplace laws. Arch Intern Med (2012) 3.77
Cognitive and behavioral outcomes after early exposure to anesthesia and surgery. Pediatrics (2011) 3.76
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
Cardiac arrest during neuraxial anesthesia: frequency and predisposing factors associated with survival. Anesth Analg (2005) 2.87
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol (2007) 2.50
Neuraxial anesthesia and analgesia in patients with preexisting central nervous system disorders. Anesth Analg (2006) 2.46
Neuraxial labor analgesia for vaginal delivery and its effects on childhood learning disabilities. Anesth Analg (2010) 2.31
Small risk of serious neurologic complications related to lumbar epidural catheter placement in anesthetized patients. Anesth Analg (2003) 2.24
The Fagerström Test for Nicotine Dependence-Smokeless Tobacco (FTND-ST). Addict Behav (2006) 2.21
Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest (2009) 2.16
Anesthetic, patient, and surgical risk factors for neurologic complications after prolonged total tourniquet time during total knee arthroplasty. Anesth Analg (2006) 2.16
Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology (2002) 2.07
Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence. Addict Behav (2003) 2.07
Predictors of survival following cardiac arrest in patients undergoing noncardiac surgery: a study of 518,294 patients at a tertiary referral center. Anesthesiology (2003) 2.02
Attention-deficit/hyperactivity disorder after early exposure to procedures requiring general anesthesia. Mayo Clin Proc (2012) 1.95
Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J Immunol (2005) 1.88
A comparison of psoas compartment block and spinal and general anesthesia for outpatient knee arthroscopy. Anesth Analg (2003) 1.84
Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol (2009) 1.82
Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med (2002) 1.81
Characterizing the epidemiology of postoperative transfusion-related acute lung injury. Anesthesiology (2015) 1.76
Perioperative cardiac arrests in children between 1988 and 2005 at a tertiary referral center: a study of 92,881 patients. Anesthesiology (2007) 1.75
Resource utilization and outcome in gravely ill intensive care unit patients with predicted in-hospital mortality rates of 95% or higher by APACHE III scores: the relationship with physician and family expectations. Mayo Clin Proc (2005) 1.64
Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells. J Mol Cell Cardiol (2006) 1.63
Increased risk associated with pulmonary artery catheterization in the medical intensive care unit. J Crit Care (2003) 1.63
Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol (2002) 1.62
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest (2003) 1.61
Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology (2003) 1.60
Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin Chem (2002) 1.59
Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem (2008) 1.57
A comparison of bleeding and transfusion in patients who undergo coronary artery bypass grafting via sternotomy with and without cardiopulmonary bypass. J Cardiothorac Vasc Anesth (2003) 1.57
Change in smoking status after spiral chest computed tomography scan screening. Cancer (2003) 1.55
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol (2005) 1.53
Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer (2005) 1.51
Residential treatment compared with outpatient treatment for tobacco use and dependence. Mayo Clin Proc (2011) 1.51
Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. FASEB J (2007) 1.50
Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther (2011) 1.49
Risk factors for laryngospasm in children during general anesthesia. Paediatr Anaesth (2008) 1.48
Anesthesia for cesarean delivery and learning disabilities in a population-based birth cohort. Anesthesiology (2009) 1.47
Effect of nitrous oxide on neurologic and neuropsychological function after intracranial aneurysm surgery. Anesthesiology (2008) 1.46
Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am J Respir Cell Mol Biol (2005) 1.45
Impact of tobacco use on the symptoms of painful temporomandibular joint disorders. Pain (2009) 1.45
Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair. Am J Physiol Cell Physiol (2014) 1.44
Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration (2005) 1.39
Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis (2010) 1.38
Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest (2005) 1.34
Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem (2002) 1.33
Risk for perioperative myocardial infarction and mortality in patients undergoing hip or knee arthroplasty: the role of anemia. Transfusion (2011) 1.30
Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res (2009) 1.29
Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.28
Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest (2005) 1.27
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol (2002) 1.25
Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy. Transfusion (2014) 1.25
Neurologic complications after neuraxial anesthesia or analgesia in patients with preexisting peripheral sensorimotor neuropathy or diabetic polyneuropathy. Anesth Analg (2006) 1.24
Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and postanesthesia care assessment. Anesthesiology (2009) 1.22
Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore) (2011) 1.21
Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation. J Biol Chem (2003) 1.21
Is smoking related to body image satisfaction, stress, and self-esteem in young adults? Am J Health Behav (2006) 1.21
Effectiveness of smoking cessation self-help materials in a lung cancer screening population. Lung Cancer (2004) 1.19
Tobacco and other substance use among Alaska Native youth in western Alaska. Am J Health Behav (2007) 1.17
Iqmik--a form of smokeless tobacco used by pregnant Alaska natives: nicotine exposure in their neonates. J Matern Fetal Neonatal Med (2005) 1.16
An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc (2006) 1.16
Pneumocystis carinii cell wall biosynthesis kinase gene CBK1 is an environmentally responsive gene that complements cell wall defects of cbk-deficient yeast. Infect Immun (2004) 1.15
Stress Management and Resilience Training (SMART) program to decrease stress and enhance resilience among breast cancer survivors: a pilot randomized clinical trial. Clin Breast Cancer (2011) 1.14
Pneumocystis cell wall beta-glucans induce dendritic cell costimulatory molecule expression and inflammatory activation through a Fas-Fas ligand mechanism. J Immunol (2006) 1.13
Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. Anesthesiology (2015) 1.12
Fitness of cell-mediated immunity independent of repertoire diversity. J Immunol (2007) 1.11
Preoperative gabapentin for acute post-thoracotomy analgesia: a randomized, double-blinded, active placebo-controlled study. Pain Pract (2011) 1.10
Association between respiratory tract diseases and secondhand smoke exposure among never smoking flight attendants: a cross-sectional survey. Environ Health (2007) 1.10
Cognitive and functional predictors and sequelae of postoperative delirium in elderly patients undergoing elective joint arthroplasty. Anesth Analg (2011) 1.09
Acute kidney injury following total joint arthroplasty: retrospective analysis. Can J Anaesth (2012) 1.09
The diagnosis of obstructive sleep apnea as a risk factor for unanticipated admissions in outpatient surgery. Anesth Analg (2003) 1.07
Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology (2008) 1.07
Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. Respir Res (2010) 1.07
Management plan to reduce risks in perioperative care of patients with presumed obstructive sleep apnea syndrome. J Clin Sleep Med (2007) 1.05
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells. J Biol Chem (2004) 1.05
Prevalence of moderate-severe pain in hospitalized children. Paediatr Anaesth (2012) 1.05
Transforming growth factor-beta1 induces heparan sulfate 6-O-endosulfatase 1 expression in vitro and in vivo. J Biol Chem (2008) 1.04
Performance improvement system and postoperative corneal injuries: incidence and risk factors. Anesthesiology (2009) 1.03
Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg (2011) 1.03
Cotinine as a biomarker of systemic nicotine exposure in spit tobacco users. Addict Behav (2004) 1.02
Second primary tumors following tobacco dependence treatments among head and neck cancer patients. Am J Clin Oncol (2007) 1.02
Transforaminal epidural clonidine versus corticosteroid for acute lumbosacral radiculopathy due to intervertebral disc herniation. Spine (Phila Pa 1976) (2011) 1.01